**FOR IMMEDIATE RELEASE**

# Appendix 3X

---

**Sydney, Australia 16th March 2012** - NuSep (ASX: NSP) as previously advised to the market, Mr Andrew Goodall was appointed to the Board of NuSep on 14 March 2012.

Attached is the Appendix 3X.

****ENDS****

**For more information please contact:**

Contact:
Tom Rowe
Company Secretary
+61 2 8415 7300
tom.rowe@nusep.com

**About NuSep**

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
- **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

**About PrIME Biologics Pte Ltd**

PrIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PrIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PrIME Biologics process is based on the **Pr**eparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many countries.

*Rule 3.19A.1*

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | **NuSep Holdings Limited** |
| **ABN** | **33 120 047 556** |

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | Andrew Goodall |
| **Date of appointment** | 14 March 2012 |

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| **Number & class of securities** |
|---|
| 17,320,000 ordinary fully paid shares<br>31,582 35 cent options<br>161,474 15 cent options |

+ See chapter 19 for defined terms.

## Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| **Name of holder & nature of interest**<br>Note: Provide details of the circumstances giving rise to the relevant interest.<br><br>N/A | **Number & class of Securities** |
|---|---|

## Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | Convertible Loan |
| **Nature of interest** | Direct |
| **Name of registered holder (if issued securities)** | N/A |
| **No. and class of securities to which interest relates** | Mr Goodall has the right to convert a loan to the Company of $300,000 together with interest accruing at 8% per annum into ordinary fully paid shares at 7 cents per share. The Loan is for a two month term and matures on 9 April 2012. |